Good morning and welcome to October. Elizabeth Cooney sitting in for Ed Silverman again today from STAT in Boston, where just the hint of crisp fall air gladdens the hearts of runners and others who wilt in summer heat. But enough with the weather and on with the news:

Endo International (ENDP), Johnson & Johnson (JNJ), and other drug makers that face sprawling litigation over the opioid crisis are exploring an unusual way to settle the cases: by participating in Purdue Pharma’s bankruptcy, the Wall Street Journal reports, according to internal documents and a person familiar with the matter. The move, if successful, could bring an end to — or at least dramatically shrink — one of the largest and most complex pieces of litigation the U.S. has ever seen.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy